Wikipedia -WSS

Wikipedia

author：knowledge 2025-08-26 10:52:32 - browse：2

Stock exchange — Drew Angerer/Getty Images

Structure Therapeutics reported Monday that its oral GLP-1 drug led to weight loss in two small studies, leading shares to surge in pre-market trading.

In a 12-week Phase 2a study, the daily pill in a capsule formulation led to 6.2% placebo-adjusted weight loss. In a separate 12-week pharmacokinetics study, the company tested a new tablet formulation of the drug, called GSBR-1290, and it led to placebo-adjusted weight loss of up to 6.9%.

Though it’s difficult to compare across different studies, the results appear to approach the levels of weight loss seen at 12 weeks in a separate Phase 2 study of Eli Lilly’s GLP-1 pill called orforglipron. That entire study lasted 36 weeks, but at 12 weeks, participants had about 6%-7% placebo-adjusted weight loss.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Moonlake's readout produced a cash windfall. Risks remain
Next article： First recipient of genetically engineered pig kidney has died

focus

WSS

Steward Health Care files for bankruptcy

Average age of first period drops to 11.9 years, study shows

Medicare says breakthrough device reimbursement rule to come by summer

Use wet bulb globe temperature, not heat index, to protect workers

Lab trade group sues FDA to halt regulation of lab

Health insurers say they are turning to AI to cut costs, improve care

focus

Wikipedia

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

explore

United colonoscopy coverage change 'may cost lives,' doctors say

Average age of first period drops to 11.9 years, study shows

Virginia high school admissions case could be legal follow

What nurses really want: sufficient staffing for patient care

The high cost of giving birth even with insurance

Readout Newsletter: Sanofi, Novavax, Maze x Shionogi news

Duchenne breakthrough therapy leaves behind pioneering families

Insmed lung disease drug hits target in key Phase 3 trial

DIEP, the 'gold standard' of breast reconstruction, is under threat

iTeos Therapeutics debuts first data on TIGIT

Wikipedia

iTeos Therapeutics debuts first data on TIGIT

iTeos Therapeutics debuts first data on TIGIT

Elevance, private equity launch primary care company

Use wet bulb globe temperature, not heat index, to protect workers

Report: NIH

It shouldn't be easy to buy synthetic DNA to recreate a deadly virus

focus

focus

leisure time

leisure time